Ambu A/S Class B ( (AMBFF) ) has released its Q2 earnings. Here is a breakdown of the information Ambu A/S Class B presented to its investors.
Ambu A/S is a Danish medtech company specializing in single-use endoscopy, anaesthesia, and patient monitoring solutions, known for its innovative approach in the healthcare sector.
In its latest earnings report for Q2 2024/25, Ambu A/S reported a robust organic revenue growth of 11.7% and an EBIT margin of 14.4% before special items, driven by strong performances in its Endoscopy Solutions and Anaesthesia & Patient Monitoring segments.
Key financial highlights include a 13.1% organic growth in Endoscopy Solutions and a 9.8% increase in Anaesthesia & Patient Monitoring. The company also launched new products, such as the Ambu SureSight™ Connect and expanded its urology portfolio, which are expected to contribute to future growth. Despite geopolitical uncertainties, Ambu maintained its financial guidance for the year, projecting an organic revenue growth of 11-14% and an EBIT margin of 13-15% before special items.
Looking ahead, Ambu remains focused on innovation and sustainability, aiming to integrate circular products and achieve net-zero emissions. The management expresses confidence in navigating external challenges and delivering on its financial targets for the fiscal year 2024/25.